Apnimed scouts $160m IPO to back late-stage sleep apnoea pill development

Tuesday, July 28, 2026Annabel Kartal AllenView original

Apnimed will use the IPO funds to progress lead candidate oxnimbi, which could become the first pill to break onto the OSA market.

Read the full article on the original site.